| CRISPR THERAPEUTICS |
| Schweiz |
| Gesundheit |
| CH0334081137 / A2AT0Z |
| 1CG (Frankfurt) / CRSP (NASDAQ) |
| FRA:1CG, ETR:1CG, 1CG:GR, NASDAQ:CRSP |
| - |
| https://crisprtx.com/ |
|
CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portf..
>Volltext.. |
| 4053.97 Mio. EUR |
| 2621.92 Mio. EUR |
| 3.56 Mio. EUR |
| -460.9 Mio. EUR |
| -493.33 Mio. EUR |
| -5.39 EUR |
| 683.45 Mio. EUR |
| 367.66 Mio. EUR |
| -347.06 Mio. EUR |
| 17.92 |
| -89.8% |
| -38.04% |
| - |
| - |
| - |
| - |
| CRISPR THERAPEUTICS |
| 04.08.26 |
|